Skip to main content

Work With BrIDGs

BrIDGs is not a grant program. Instead of receiving grant funds, selected investigators partner with NIH intramural scientists to complete preclinical therapy development studies at no cost to the investigator.

Work With BrIDGs

Partnering investigators and scientists use BrIDGs expertise and resources to produce data for Investigational New Drug applications to a regulatory authority, such as the U.S. Food and Drug Administration.

BrIDGs allows partnerships on potential therapies for any disease or disorder. Eligible partnering organizations include academic institutions, not-for-profit organizations and small businesses that meet the criteria for the Small Business Innovation Research program. Foreign academic and nonprofit institutions, as well as NIH intramural researchers, can work with BrIDGs.

Learn more about working with BrIDGs:

BrIDGs Operational Model

BrIDGs staff partner with researchers in need of preclinical therapeutics development expertise and resources to advance candidate therapeutics into clinical trials. Researchers with enough preliminary data can use BrIDGs capabilities to put a preclinical product development plan into action. In general, available expertise and contract resources include synthesis, formulation, pharmacokinetic and toxicology services.

Pre-existing intellectual property (IP) rights are retained by the owner, which allows BrIDGs to function as a non-dilutive investment in exciting preclinical therapeutics development projects and to maximize the competitiveness of therapeutic agents for more private-sector funding.